One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease
doi : 10.1111/dom.15773
Research advances in understanding crosstalk between organs and pancreatic β-cell dysfunction
doi : 10.1111/dom.15787
Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action
doi : 10.1111/dom.15789
Follow-up and monitoring programme in children identified in early-stage type 1 diabetes during screening in the general population of Italy
doi : 10.1111/dom.15779
Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial
doi : 10.1111/dom.15738
Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta-analysis
doi : 10.1111/dom.15752
Impact of non-alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi-cohort longitudinal study
doi : 10.1111/dom.15758
Prevalence of very high cardiovascular disease risk in patients with type 2 diabetes mellitus: A population-based cross-sectional screening study
doi : 10.1111/dom.15763
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
doi : 10.1111/dom.15769
Bariatric surgery and all-cause mortality: A methodological review of studies using a non-surgical comparator
doi : 10.1111/dom.15771
Adherence to the Dietary Approaches to Stop Hypertension (DASH) diet is associated with lower visceral and hepatic lipid content in recent-onset type 1 diabetes and type 2 diabetes
doi : 10.1111/dom.15772
Systematic review of disparities in continuous glucose monitoring and insulin pump utilization in the United States: Key themes and evidentiary gaps
doi : 10.1111/dom.15774
Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta-analysis
doi : 10.1111/dom.15777
Time trends in hypertension and diabetes prevalence by body mass index categories in Brazilian adults from 2006 to 2023
doi : 10.1111/dom.15780
Topical menthol, a pharmacological cold mimic, induces cold sensitivity, adaptive thermogenesis and brown adipose tissue activation in mice
doi : 10.1111/dom.15781
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status
doi : 10.1111/dom.15782
Trends in hospitalization for cardio-renal disease and mortality in people with type 1 diabetes in England, 2009–2019
doi : 10.1111/dom.15783
Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching
doi : 10.1111/dom.15784
Circulating small non-coding RNAs are associated with the insulin-resistant and obesity-related type 2 diabetes clusters
doi : 10.1111/dom.15786
Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study
doi : 10.1111/dom.15788
Clinical factors influencing the success rate of radioiodine treatment for Graves' disease
doi : 10.1111/dom.15790
The causal relationship between plasma protein-to-protein ratios and type 2 diabetes and its complications: Proteomics mendelian randomization study
doi : 10.1111/dom.15792
Individual treatment effects of sodium-glucose co-transporter-2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real-world data
doi : 10.1111/dom.15793
Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme
doi : 10.1111/dom.15794
Risk of new-onset diabetes and efficacy of pharmacological weight loss therapy
doi : 10.1111/dom.15798
Persistent disparities in insulin pump uptake despite a universal pump programme for type 1 diabetes in Ontario, Canada
doi : 10.1111/dom.15799
Comparison of renal prognosis between dipeptidyl peptidase-4 inhibitor users and non-users
doi : 10.1111/dom.15800
The effects of time-restricted eating alone or in combination with probiotic supplementation in comparison with a calorie-restricted diet on endocrine and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial
doi : 10.1111/dom.15801
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
doi : 10.1111/dom.15802
Bariatric arterial embolization slows gastric emptying and improves postprandial glycaemia in obese dogs with impaired glucose tolerance
doi : 10.1111/dom.15803
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non-users. A propensity score matching National Cohort Study
doi : 10.1111/dom.15804
Obesity-induced upregulation of miR-483-5p impairs the function and identity of pancreatic β-cells
doi : 10.1111/dom.15805
Cost-effectiveness analysis of a digital diabetes-prevention programme versus an in-person diabetes-prevention programme in people with prediabetes in the United States
doi : 10.1111/dom.15807
Body weight change associated kidney outcomes of sodium–glucose cotransporter new users
doi : 10.1111/dom.15808
Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis
doi : 10.1111/dom.15809
Attenuation of brown adipocyte whitening in high-fat diet-induced obese rats: Effects of melatonin and β-hydroxybutyrate on Cidea, Fsp27 and MT1 expression
doi : 10.1111/dom.15810
Oxytocin does not acutely improve glucose tolerance in men with type 2 diabetes
doi : 10.1111/dom.15812
Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study
doi : 10.1111/dom.15814
Global deletion of G protein-coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β-cell turnover
doi : 10.1111/dom.15816
Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial
doi : 10.1111/dom.15817
The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice
doi : 10.1111/dom.15820
Associations of childhood and adulthood body size, and child-to-adult body size change with adult telomere length
doi : 10.1111/dom.15825
Metabolically healthy obesity and left ventricular geometric remodelling in Chinese children
doi : 10.1111/dom.15826
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes
doi : 10.1111/dom.15827
Efficacy, adherence and persistence of various glucagon-like peptide-1 agonists: nationwide real-life data
doi : 10.1111/dom.15828
Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study
doi : 10.1111/dom.15830
Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data
doi : 10.1111/dom.15833
Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: The Impact GLP-1 CKD study
doi : 10.1111/dom.15834
Perceptions, attitudes and barriers to effective obesity care among people living with obesity and healthcare professionals in China: The ACTION-China study
doi : 10.1111/dom.15837
Dark tea consumption is associated with a reduced risk of dysglycaemia and increased urinary glucose and sodium excretion in Chinese adults
doi : 10.1111/dom.15839
The effect of Mankai plant consumption on postprandial glycaemic response among patients with type 2 diabetes: A randomized crossover trial
doi : 10.1111/dom.15840
Joint effects of sleep disturbance and renal function impairment on incident new-onset severe metabolic dysfunction-associated steatotic liver disease
doi : 10.1111/dom.15841
LEAP2 is associated with impulsivity and reward sensitivity depending on the nutritional status and decreases with protein intake in humans
doi : 10.1111/dom.15850
Cystic fibrosis-related diabetes develops from a combination of insulin secretion defects and insulin resistance
doi : 10.1111/dom.15844
Clinical evidence for high-risk CE-marked medical devices for glucose management: A systematic review and meta-analysis
doi : 10.1111/dom.15849
Time in tight range in automated insulin delivery system users: Real-world data from children and adolescents with type 1 diabetes
doi : 10.1111/dom.15791
A novel structured, volume-based, weight-loss and health programme combined with respiratory muscle training helps reduce weight and cardiovascular risk in people with obesity
doi : 10.1111/dom.15795
Regional disparities in type 2 diabetes prevalence and associated risk factors in the United States
doi : 10.1111/dom.15797
Newer glucose-lowering drugs and risk of suicidal ideation and behaviours: A network meta-analysis of randomized outcome trials
doi : 10.1111/dom.15822
Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus
doi : 10.1111/dom.15823
Perceptions, attitudes and barriers to effective obesity care among people with obesity and health care professionals in India
doi : 10.1111/dom.15824
Continuous glucose monitoring and all-cause mortality in insulin-using population with diabetes and cognitive impairment
doi : 10.1111/dom.15842
Correlation of body metrics, assessed with a portable scanning device, with established anthropometrics in people with obesity
doi : 10.1111/dom.15776
Treatment with sodium-glucose cotransporter 2 inhibitors and risk of lower-limb amputations
doi : 10.1111/dom.15775
Adapting study designs of Mendelian randomization for disease complications: Insights from type 1 diabetes complications research
doi : 10.1111/dom.15813
